Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05850494 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT05850494 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 52 participants.
The verdict
NCT05850494, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
A study to assess bronchospasm potentially induced by HFO MDI as compared with HFA MDI in participants with well controlled or partially controlled asthma
Interventions
- DRUG HFA MDI
- DRUG HFO MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05850494
The ClinicalTrials.gov registry entry for NCT05850494 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HFA MDI is the first listed.
NCT05850494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05850494 about?
NCT05850494 is a clinical study titled "Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma". A study to assess bronchospasm potentially induced by HFO MDI as compared with HFA MDI in participants with well controlled or partially controlled asthma
What is the current status of trial NCT05850494?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2023-05-02. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT05850494?
The interventions under investigation include: HFA MDI (DRUG), HFO MDI (DRUG).
Who is sponsoring clinical trial NCT05850494?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.